share_log

Cantor Fitzgerald Downgrades Cerevel Therapeutics Hldg to Neutral, Raises Price Target to $45

Benzinga ·  Dec 7, 2023 05:50

Cantor Fitzgerald analyst Charles Duncan downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Overweight to Neutral and raises the price target from $38 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment